Industrials

Aramark (ARMK)

$10.6B
Market Cap
33.8
P/E Ratio
1.15
Beta
1.20%
Dividend Yield
Piotroski 7/9Altman Z 2.3 Gray ZoneBeneish M -2.63 CleanROIC−WACC -2.8%

Quantitative Summary

Deterministic

ARMK trades at 33.8x earnings, roughly in line with its sector average of 44.7x. Strong operational fundamentals (Piotroski 7/9) with Altman Z of 2.3.

Generated deterministically from quant metrics and financial statements. Not a recommendation.

Algorithmic Teardown

AI-Generated

The fundamental economics of Aramark present a distinct divergence between operational stability and capital efficiency. While the Piotroski F-Score of 7/9 and Beneish M-Score of -2.63 signal strong financial health with minimal earnings manipulation risk, the company generates negative value creation relative to its cost of equity; an ROIC-WACC spread of -2.8% indicates that capital is being deployed below the hurdle rate required by investors. This inefficiency stems from a low net margin of 1.8%, which constrains returns despite robust revenue growth of 6.3%. Within the DuPont framework, this suggests earnings quality relies heavily on top-line expansion rather than leverage or high-margin operations, as evidenced by an ROE that is likely compressed by thin spreads and moderate turnover relative to peers in a sector averaging higher valuation multiples.

Valuation metrics reflect a significant premium over historical norms and peer group averages, with the current P/E of 33.8x trailing the industrials sector average of 44.9x only marginally while implying aggressive future expectations that may not align with current capital efficiency. A DCF analysis pegging fair value at $41 suggests a substantial gap between market pricing and intrinsic worth derived from discounted cash flows, potentially indicating that the market is pricing in growth rates or margin expansion scenarios that exceed the company's demonstrated ability to generate returns above its weighted average cost of capital. The disparity between the modest 6.3% revenue growth and the elevated multiple implies that current valuations are sensitive to any deviation in future performance assumptions.

Risk assessment reveals a complex profile where strong balance sheet metrics mask underlying value destruction from negative ROIC-WACC spreads. Although the Altman Z-Score of 2.3 indicates a moderate safety margin against bankruptcy, the structural inability to generate returns exceeding the cost of capital creates persistent drag on shareholder equity growth unless leverage is increased or operating margins expand significantly. Investors must weigh the security offered by high F-scores and low manipulation risk against the fundamental reality that current operations fail to meet the return thresholds necessary to justify the existing premium valuation without substantial operational transformation.

Generated by LLM from quantitative data inputs. May contain inaccuracies. Not investment advice.

DCF Sandbox

Interactive

Sensitivity Matrix

TG ↓ / WACC →7.2%9.2%11.2%
2%$55$34$22
3%$69$41$26
4%$93$50$31

Center = base case. Green = >10% upside, Red = >10% downside vs .

Pre-computed DCF: WACC=9.2%, terminal growth 3%. Fair value $41 (+0.0%). Not investment advice.

Valuation Context

33.8x
ARMK P/E
44.7x
Sector Avg
-25%
vs Sector

Price Chart with Moving Averages

Loading chart...
SMA 50 SMA 200

Quant Health Deep Dive

7/9
Piotroski F-Score
Strong — high operational efficiency and profitability signals
2.3
Altman Z-Score
Grey Zone — between 1.8 and 3.0 thresholds. Thresholds: >3 safe, 1.8–3 grey, <1.8 distress.
-2.63
Beneish M-Score
Below threshold — no statistical earnings quality concern per Beneish model. Threshold: <-2.22 = below threshold.

Profitability & Value Creation

8.4%
Gross Margin
1.8%
Net Margin
6.4%
ROIC
9.2%
WACC
ROIC − WACC Spread: -2.8%— Negative spread.
+6.3%
Revenue Growth (YoY)
+24.3%
Earnings Growth (YoY)
431.8M
Free Cash Flow
26%
FCF Payout Ratio

✅ Conservative payout — room for dividend increases.

Balance Sheet Health

3.21x
Debt / Equity
0.99x
Current Ratio
2.2x
Interest Coverage
3.7x
Net Debt / EBITDA
2.82%
FCF Yield
1.3B
EBITDA

Earnings Surprise History

Q4
✓ Beat
Est: $0.33
Act: $0.34
+2.7%
Q3
✓ Beat
Est: $0.40
Act: $0.40
0.0%
Q2
✗ Miss
Est: $0.65
Act: $0.57
-12.7%
Q1
✓ Beat
Est: $0.51
Act: $0.51
+0.3%

EPS estimates vs actuals for the most recent reported quarters. Source: yfinance.

Underwater (Drawdown from Peak)

How far below the all-time high the price has been over time. Deeper = more pain for holders.

Loading drawdown chart...

Rolling 60-Day Beta vs S&P 500 (VOO)

How the stock's sensitivity to market moves changes over time. β > 1 = more volatile than the market.

Loading beta chart...
Rolling Beta Market (β = 1.0)

Fundamentals

15.4
Forward P/E
PEG Ratio
3.29
Price/Book
3M
Avg Volume
$44.49
52W High
$29.92
52W Low
52W Range Position

Passive Flow Attribution

ETF Draft Effect
$767M
Tracked Passive Exposure
8
ETFs Holding ARMK
0.18%
Avg Weight in ETFs
$422B
Total ETF AUM

When investors buy or sell ETFs like MDYV or SPMD, the fund manager is mechanically forced to buy or sell ARMK shares regardless of Aramark's individual fundamentals. We estimate $767M of passive capital is structurally linked to ARMK through 8 tracked ETFs. Passive flows have a limited but growing influence on ARMK's daily trading dynamics.

Passive exposure = Σ (ETF AUM × stock weight in ETF) across 8 tracked ETFs. Actual passive ownership is larger (includes mutual funds). Not investment advice.

ETF Contagion Visualizer

Simulate a price drop in Aramark to visualize passive redemption contagion across ETFs and collateral stocks.

ARMK Shock
-0%
Est. Passive Redemption
$0
Systemic Risk
STABLE
ARMKEpicenterVBETFVXFETFVBRETFFLEXMed RiskRSLow RiskSNXMed RiskUSFDLow RiskBWAMed Risk
ARMK Price Drop (%)0

If Aramark (ARMK) experiences a significant drawdown, ETF redemptions can create collateral selling pressure on co-held stocks. Our model identifies FLEX LTD (FLEX) as the most exposed collateral stock, sharing 2 ETFs with ARMK. This is the "Passive Contagion" effect described in the Inelastic Market Hypothesis.

Contagion model based on shared ETF exposure and constituent weights across 13 tracked ETFs. Estimated selling pressure is a simplified model — actual impact depends on market liquidity, ETF redemption mechanics, and market-maker activity.

ARMK Ownership Dynamics

Ticker
ARMK

Float lock-up computed from 13 ETFs tracked by SecuritiesDB. Actual passive ownership is higher (includes mutual funds, pension funds, etc.).

ARMK Capital Efficiency

How efficiently does Aramark convert operating profits into free cash? The FCF Conversion ratio measures the gap between accounting earnings and real cash generation.

Free Cash Flow
$432M
EBITDA
$1.3B
FCF Conversion
34%
Reinvestment Rate
66%
34% of EBITDA → Free Cash
0% (cash burn)25% (low)50% (efficient)100% (pure cash)
ROIC
6.4%
ROIC − WACC Spread
-2.8%

Aramark converts 34% of its EBITDA into free cash flow, a moderate conversion rate — significant EBITDA is consumed by capital expenditures, working capital changes, or interest payments. The 66% reinvestment rate signals aggressive capacity expansion. However, the ROIC-WACC spread is negative (-2.8%), suggesting reinvested capital is destroying shareholder value.

Capital efficiency = Free Cash Flow ÷ EBITDA. Reinvestment = (EBITDA − FCF) ÷ EBITDA. Metrics from latest annual filings. Not investment advice.

Fails-to-Deliver (FTD) History

SEC-reported settlement failures. Elevated FTDs can indicate high short-selling pressure, operational settlement issues, or naked shorting activity.

DateFailed SharesClose PriceNotional Value
2026-05-14500,000$50.75$25.4M
2026-05-13500,000$48.41$24.2M
2026-05-12500,000$44.56$22.3M
2026-05-06182$45.26$8,237.32
2026-03-26833$41.47$34,544.51
2026-03-25183$40.23$7,362.09
2026-03-24105$40.29$4,230.45
2026-03-19606$39.85$24,149.1
2026-03-171,068$40.45$43,200.6
2026-03-13259$39.99$10,357.41
2026-03-103,527$40.32$142,208.64
2026-03-042$40.86$81.72
2026-02-1913$40.16$522.08
2026-02-1340$39.16$1,566.4
2026-02-04224$38.06$8,525.44
2026-02-036,299$38.34$241,503.66
2026-01-20329$39.62$13,034.98
2026-01-074$38.59$154.36
2025-12-2910,259$37.42$383,891.78
2025-12-2326,742$38.37$1.0M
2025-12-12501$37.61$18,842.61
2025-11-212,468$36.98$91,266.64

Source: SEC Regulation SHO FTD data. Data is reported with a ~30 day delay. High FTD quantities relative to average daily volume may indicate settlement stress.

Compare ARMK to Peers

Quant metrics computed deterministically from financial statements and price data. Updated: N/A.

SecuritiesDB provides programmatic data aggregation for informational purposes only. None of the metrics, summaries, or algorithmic flags constitute a recommendation to buy or sell any security.